Nursing facility
Rex Hospital INC.
Rex Hospital INC. was paid $25.33M by Medicaid between Jan 2018 and Dec 2024, across 216 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoREX HOSPITAL INC.
RALEIGH, NC 27607
RALEIGH, NC 27607
33aNPI1497797088assigned 06/11/2006
33bProvider typeInpatient Hospice
28Total paid$25.33M
24GClaims1,043,063
24DCodes billed216
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 78,522 | $1.32M | |
| 2019 | 85,818 | $1.56M | |
| 2020 | 93,691 | $1.29M | |
| 2021 | 170,816 | $3.00M | |
| 2022 | 176,012 | $5.60M | |
| 2023 | 223,034 | $6.14M | |
| 2024incomplete | 215,170 | $6.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 19,187 | 17,080 | $5.72M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 25,537 | 22,992 | $5.16M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.5% | 7,197 | 6,559 | $1.15M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.9% | 28,040 | 24,368 | $740K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.9% | 28,057 | 24,383 | $729K |
| 80053 | Comprehensive metabolic panel | 2.4% | 70,002 | 61,570 | $612K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 79,112 | 67,263 | $593K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 9,972 | 7,125 | $581K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.0% | 16,376 | 14,888 | $494K |
| 80061 | Lipid panel | 1.9% | 36,029 | 32,808 | $489K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 13,081 | 10,646 | $452K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.7% | 17,498 | 15,087 | $440K |
204 more codes
| 99285 | Emergency room visit (most serious) | 1.6% | 1,091 | $403K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 23,613 | $375K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 5,837 | $327K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.3% | 12,127 | $325K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 27,877 | $273K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 114,822 | $260K |
| 86780 | <1% | 17,079 | $243K | |
| 86803 | <1% | 15,900 | $242K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 8,879 | $220K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,450 | $202K |
| 82728 | <1% | 13,786 | $200K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,512 | $188K |
| 80050 | General health panel | <1% | 16,156 | $177K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,686 | $165K |
| 85027 | <1% | 23,920 | $163K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,483 | $147K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,098 | $146K |
| 82607 | <1% | 8,793 | $139K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,105 | $137K |
| J3490 | Unclassified drugs | <1% | 29,843 | $135K |
| 84439 | <1% | 13,799 | $131K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,931 | $130K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,649 | $119K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,935 | $108K |
| 86480 | <1% | 1,484 | $106K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,560 | $100K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,565 | $94K |
| 83550 | <1% | 9,468 | $91K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,443 | $82K |
| 87340 | <1% | 8,535 | $81K | |
| 83880 | <1% | 2,410 | $81K | |
| 80074 | <1% | 1,655 | $80K | |
| 86762 | <1% | 4,863 | $76K | |
| 83540 | <1% | 10,209 | $73K | |
| 86003 | <1% | 13,116 | $71K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 74 | $69K |
| 83655 | <1% | 5,416 | $69K | |
| 87077 | <1% | 8,082 | $69K | |
| 81001 | <1% | 20,676 | $68K | |
| 86850 | <1% | 5,492 | $64K | |
| 81513 | <1% | 9,349 | $63K | |
| 86787 | <1% | 4,460 | $62K | |
| 84403 | <1% | 2,135 | $60K | |
| 83516 | <1% | 5,227 | $59K | |
| 87081 | <1% | 8,414 | $57K | |
| 83970 | <1% | 1,633 | $56K | |
| 82570 | <1% | 9,624 | $51K | |
| 82746 | <1% | 3,318 | $51K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,904 | $48K |
| 87186 | <1% | 5,222 | $47K | |
| 84481 | <1% | 2,407 | $45K | |
| 84153 | <1% | 2,339 | $42K | |
| 83001 | <1% | 2,040 | $41K | |
| 84146 | <1% | 1,884 | $40K | |
| 83735 | <1% | 5,981 | $39K | |
| 84402 | <1% | 1,311 | $37K | |
| 82670 | <1% | 1,470 | $37K | |
| 82652 | <1% | 1,068 | $32K | |
| 86140 | <1% | 5,776 | $32K | |
| 82950 | <1% | 6,202 | $32K | |
| 83690 | <1% | 4,404 | $32K | |
| 82043 | <1% | 5,492 | $32K | |
| 84702 | <1% | 3,336 | $31K | |
| 87150 | <1% | 850 | $31K | |
| 81025 | <1% | 3,631 | $30K | |
| 80076 | <1% | 3,591 | $30K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,191 | $26K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 760 | $26K |
| 82784 | <1% | 2,766 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 567 | $26K |
| 87522 | Neg quan hep c or qual rna | <1% | 634 | $22K |
| 86696 | <1% | 1,050 | $21K | |
| 82951 | <1% | 1,273 | $19K | |
| 87070 | <1% | 1,904 | $18K | |
| 83002 | <1% | 856 | $18K | |
| 87536 | <1% | 413 | $18K | |
| 82105 | <1% | 984 | $17K | |
| 86039 | <1% | 1,700 | $17K | |
| 84484 | <1% | 1,941 | $16K | |
| 86360 | <1% | 349 | $16K | |
| 86901 | <1% | 5,238 | $16K | |
| 84156 | <1% | 4,085 | $16K | |
| 86900 | <1% | 5,192 | $16K | |
| 86376 | <1% | 1,046 | $16K | |
| 86706 | <1% | 1,451 | $16K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 154 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 255 | $16K |
| 85610 | <1% | 3,839 | $14K | |
| 86359 | <1% | 372 | $14K | |
| 84425 | <1% | 780 | $14K | |
| 82247 | <1% | 2,463 | $14K | |
| 86695 | <1% | 1,051 | $14K | |
| 82565 | <1% | 1,887 | $11K | |
| 84480 | <1% | 714 | $11K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 672 | $11K |
| 84460 | <1% | 2,754 | $10K | |
| 84450 | <1% | 2,576 | $10K | |
| 84144 | <1% | 467 | $10K | |
| 87205 | <1% | 2,010 | $9K | |
| 83615 | <1% | 1,673 | $9K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 245 | $9K |
| 84550 | <1% | 2,553 | $9K | |
| 82248 | <1% | 2,153 | $9K | |
| 85651 | <1% | 2,455 | $9K | |
| 83020 | <1% | 672 | $9K | |
| 82533 | <1% | 385 | $8K | |
| 86704 | <1% | 621 | $8K | |
| 86431 | <1% | 1,348 | $8K | |
| 86255 | <1% | 483 | $8K | |
| 84630 | <1% | 801 | $8K | |
| 84446 | <1% | 660 | $8K | |
| 83525 | <1% | 634 | $8K | |
| 82525 | <1% | 705 | $7K | |
| 84590 | <1% | 731 | $7K | |
| 85045 | <1% | 1,571 | $7K | |
| 84597 | <1% | 626 | $7K | |
| 88142 | <1% | 331 | $7K | |
| 82977 | <1% | 1,178 | $6K | |
| 82627 | <1% | 291 | $6K | |
| 87210 | <1% | 2,984 | $6K | |
| 86235 | <1% | 195 | $5K | |
| 86038 | <1% | 408 | $5K | |
| 85652 | <1% | 2,158 | $5K | |
| 84100 | <1% | 1,583 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $5K |
| 85730 | <1% | 820 | $5K | |
| 82952 | <1% | 1,031 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 617 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 137 | $4K |
| 86225 | <1% | 241 | $4K | |
| 83993 | <1% | 134 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,143 | $4K |
| 82465 | <1% | 542 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28 | $3K |
| 87507 | <1% | 16 | $3K | |
| 82550 | <1% | 461 | $3K | |
| 86708 | <1% | 223 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 282 | $3K |
| 86200 | <1% | 159 | $3K | |
| 36416 | <1% | 2,425 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 226 | $2K |
| 86800 | <1% | 117 | $2K | |
| 81511 | <1% | 1,480 | $2K | |
| 85018 | <1% | 828 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 703 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 198 | $2K |
| 86160 | <1% | 148 | $2K | |
| 87529 | <1% | 56 | $2K | |
| 81329 | <1% | 106 | $2K | |
| 80197 | <1% | 174 | $2K | |
| 80069 | <1% | 226 | $2K | |
| 87449 | <1% | 123 | $2K | |
| 0097U | <1% | 36 | $1K | |
| 82150 | <1% | 162 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $1K |
| 80164 | <1% | 98 | $1K | |
| 87209 | <1% | 45 | $1K | |
| 82785 | <1% | 55 | $1K | |
| 83021 | <1% | 107 | $984.41 | |
| 83520 | <1% | 66 | $890.88 | |
| 85660 | <1% | 145 | $813.32 | |
| 85014 | <1% | 429 | $779.83 | |
| 83519 | <1% | 54 | $779.47 | |
| 82103 | <1% | 44 | $755.98 | |
| 87338 | <1% | 57 | $741.23 | |
| 87075 | <1% | 65 | $638.90 | |
| 83498 | <1% | 14 | $622.89 | |
| J2704 | Injection, propofol, 10 mg | <1% | 107 | $564.64 |
| 87177 | <1% | 45 | $530.44 | |
| 87324 | <1% | 89 | $529.86 | |
| C1769 | Guide wire | <1% | 14 | $521.60 |
| 86677 | <1% | 26 | $515.22 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 29 | $484.33 |
| 87563 | <1% | 17 | $467.40 | |
| 82310 | <1% | 66 | $382.38 | |
| 82390 | <1% | 28 | $378.27 | |
| 83721 | <1% | 430 | $357.07 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 14 | $344.43 |
| 86592 | <1% | 76 | $337.90 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $298.20 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 14 | $285.01 |
| 84132 | <1% | 44 | $247.10 | |
| 83701 | <1% | 13 | $226.40 | |
| 82947 | <1% | 52 | $221.58 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 12 | $194.56 |
| 80177 | <1% | 12 | $175.09 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 35 | $159.92 |
| 84478 | <1% | 112 | $147.11 | |
| 83718 | <1% | 12 | $128.52 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 22 | $84.48 |
| 87147 | <1% | 14 | $83.85 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 73 | $64.67 |
| 82040 | <1% | 13 | $60.10 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 17 | $46.17 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $44.05 |
| 84436 | <1% | 12 | $42.04 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 27 | $31.52 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 29 | $25.98 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 23 | $14.52 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17 | $9.66 |
| 81005 | <1% | 12 | $5.40 | |
| 84520 | 0% | 14 | $0.00 | |
| 80304 | 0% | 37 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMATHEW, BENJAMIN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Rex Surgery Center of Wakefield, LLC | Raleigh, NC | $141K |
| Rex Surgery Center of Cary LLC | Cary, NC | $109K |
| Rex Hospital, INC. | Raleigh, NC | $936.33 |
| Rex Radiation Oncology, LLC | Raleigh, NC | $868.13 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.